Sébastien Ottaviani

Dr. Sébastien Ottaviani


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PMPeter Mandl
Peter Mandl
MDMaria Antonietta D’AGostino
Maria Antonietta D’AGostino
VNVictoria Navarro-Compán
Victoria Navarro-Compán
IGIrina Geßl
Irina Geßl
GSGarifallia Sakellariou
Garifallia Sakellariou
Georgios FilippouGeorgios Filippou
Georgios Filippou
Objective To formulate evidence-based recommendations and overarching principles on the use of imaging in the clinical management of crystal-induced arthropathies (CiAs). Methods An international task force of 25 rheumatologists, radiologists, methodologists, healthcare professionals and patient research partners from 11 countries was formed according to the EULAR standard operating procedures. Fourteen key questions on the role of imaging in the most common forms of CiA were generated. The CiA assessed included gout, calcium pyrophosphate deposition disease and basic calcium phosphate deposition disease. Imaging modalities included conventional radiography, ultrasound, CT and MRI. Experts applied research evidence obtained from four systematic literature reviews using MEDLINE, EMBASE and CENTRAL. Task force members provided level of agreement (LoA) anonymously by using a Numerical Rating Scale from 0 to 10. Results Five overarching principles and 10 recommendations were developed encompassing the role of imaging in various aspects of patient management: making a diagnosis of CiA, monitoring inflammation and damage, predicting outcome, response to treatment, guided interventions and patient education. Overall, the LoA for the recommendations was high (8.46–9.92). Conclusions These are the first recommendations that encompass the major forms of CiA and guide the use of common imaging modalities in this disease group in clinical practice.

1 December 2023 in RMD Open
Verified
Journal Article
Open access
PDF file
PJPierre-Antoine Juge
Pierre-Antoine Juge
LWLidwine Wémeau-Stervinou
Lidwine Wémeau-Stervinou
SOSébastien Ottaviani
Sébastien Ottaviani
GDGuillaume Desjeux
Guillaume Desjeux
JZJoe Zhuo
Joe Zhuo
PDPhilippe Dieudé
Philippe Dieudé
Objectives Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). The objectives of this study were to estimate mortality rate in patients with RA-ILD and identify factors affecting mortality. Methods Data from a French national claims database (Système National des Données de Santé) from 2013 to 2018 were analysed. Adults with an RA diagnosis (International Classification of Diseases (ICD)-10 codes M05, M06.0, M06.8 and M06.9) were included. ILD diagnosis was defined with ICD-10 code J84. Mortality rates were compared between patients with RA with and without ILD, using Cox proportional hazards regression, after matching 1:1 for age, sex, age at RA-ILD onset and RA duration. Results Among 173 132 patients with RA, 4330 (3%) also had ILD (RA-ILD). After matching, RA-ILD was associated with an increased mortality rate (HR 3.4, 95% CI 3.1 to 3.9). The HR for mortality was greater for: patients aged <75 years (HR 4.8, 95% CI 3.9 to 5.9) versus ≥75 years (HR 3.0, 95% CI 2.6 to 3.5); patients with ILD onset occurring before RA onset (HR 8.4, 95% CI 5.5 to 13.0) versus ILD onset occurring after RA onset (HR 2.9, 95% CI 2.6 to 3.3); and men (HR 5.2, 95% CI 4.4 to 6.2) versus women (HR 3.6, 95% CI 3.0 to 4.2). Conclusion In this nationwide cohort study, RA-ILD was associated with increased mortality rate (vs in patients with RA without ILD), notably for those aged <75 years, those whose ILD preceded RA onset and men.

1 December 2020 in Joint Bone Spine
Verified
Journal Article
Closed access
EEEsther Ebstein
Esther Ebstein
MFMarine Forien
Marine Forien
ENEleonora Norkuviene
Eleonora Norkuviene
PRPascal Richette
Pascal Richette
GMGaël Mouterde
Gaël Mouterde
SOSébastien Ottaviani
Sébastien Ottaviani

1 October 2018 in Joint Bone Spine
Verified
Journal Article
Closed access
MFMarine Forien
Marine Forien
ACAlice Combier
Alice Combier
AGAnaïs Gardette
Anaïs Gardette
EPElisabeth Palazzo
Elisabeth Palazzo
PDPhilippe Dieudé
Philippe Dieudé
SOSébastien Ottaviani
Sébastien Ottaviani

22 May 2023 in Rheumatology
Verified
Journal Article
Closed access
PDF file
JDJulien Damart
Julien Damart
Georgios FilippouGeorgios Filippou
Georgios Filippou
Mariano AndrésMariano Andrés
Mariano Andrés
ECedoardo cipolletta
edoardo cipolletta
SSSilvia Sirotti
Silvia Sirotti
Tristan PascartTristan Pascart
Tristan Pascart
Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. To describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in 7 European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. 194 treatments were initiated in 129 patients. Colchicine (was used first-line in n = 73/86), methotrexate (used first-line in n = 14/36), anakinra (n = 27) and tocilizumab (n = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-months on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%)(p< 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (p= 0.10). Adverse events lead to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab, all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.

22 December 2021 in Joint Bone Spine
Verified
Journal Article
Closed access
SOSébastien Ottaviani
Sébastien Ottaviani
PJPierre-Antoine Juge
Pierre-Antoine Juge
MFMarine Forien
Marine Forien
EEEsther Ebstein
Esther Ebstein
EPElisabeth Palazzo
Elisabeth Palazzo
PDPhilippe Dieudé
Philippe Dieudé